Summary.
Five insulin treated diabetics were studied on three consecutive days. Overnight variable intravenous insulin infusions were used before each study to maintain normoglycaemia and to calculate the optimal basal insulin infusion rate (1.1 _ 0.1 U/h) which was then kept constant throughout the study day. A standard 400 kCal breakfast with 25 g xylose was given at 0800 h. When the blood glucose rose above 4.1 mmol/1, an external artificial pancreas was used to infuse either extra insulin (day INS) or somatostatin for either 3 h (day som) or the entire 8 h experimental period (day SOM). Peak post-prandial blood glucose values were similar on all three days. The blood glucose rebounded after the cessation of the somatostatin infusion on day som. Post-prandial blood xylose peaks were lowered by somatostatin on both days but rebounded after the cessation of the somatostatin infusion on day som. The area under the plasma and urinary xylose curves was lowered by somatostatin only on day SOM. Growth hormone and glucagon levels were not statistically different on all 3 days. Thus somatostatin, when added to an optimal insulin infusion, minimised the insulin requirements by slowing intestinal absorption, but led to rebound hyperglycaemia if not feedback controlled.
Key words: Somatostatin, insulin infusion, artificial pancreas, xylose, carbohydrate absorption, glucagon, growth hormone Continuous insulin delivery systems using feedback (artificial pancreas) or preprogrammed (open-loop) control devices are currently the most effective methods of restoring a normal glycaemic profile in diabetic subjects [1] . Excessive insulin administration is an unavoidable problem with all such peripheral infusion [2, 3] , particularly post-prandially [4] . Somatostatin infusion has been reported to lower the subcutaneous insulin requirements in insulin dependent diabetics [5, 6] . Thus, the present study was carried out to establish whether somatostatin when added post-prandially to a basal IV insulin infusion might obviate the need for high post-prandial doses of insulin. The opportunity was also taken to study the effects of this bi-hormonal infusion on circulating growth hormone and glucagon and the absorption of xylose.
Subjects and Methods

Subjects
Informed consent was obtained from five insulin treated stable uncomplicated diabetics, whose clinical characteristics are shown in Table 1 . No residual insulin secretion was detected in any of the patients by using urinary C-peptide determinations. No patient was taking any drug other than insulin, or suffered from any disease other than diabetes at the time of the study. 
Experimental Protocol
Subjects were studied at bed-rest on three consecutive randomlyordered days from 0800 h to 1600 h. On the night preceding each period of study, insulin was infused IV by a variable rate pump in order to begin each experiment at normoglycaemic levels. In addition, the mean individual basal infusion rate was calculated from the first night of infusion and then held constant throughout the three 8 h studies.
A standard breakfast, containing 400 kCal (40% carbohydrate, 20% protein and 40% fat) was given at 0800 h together with 25 g xylose (Prolabo, France) dissolved in 200 ml water. No additional meal or drink was given before 1600 h. When blood See Table 2 for abbreviations. *: p < 0.05 **: p < 0.01 glucose rose above 4.1 mmol/l, an infusion given by an external artificial pancreas [7] was superimposed on the basal constant insulin rate until the blood glucose returned to 6.0 retool/1 or less. On day INS the reservoir of the artificial pancreas was filled with insulin (Actrapid), Novo) diluted in 0.154 mmol/1) saline to a final concentration of 3 U/ml. According to the algorithm used [8] the maximum infusion rate was 15 U/h. On day som insulin was replaced in the reservoir by cyclic somatostatin (Clin-Midy, France) diluted in 0.154 mmol/1 saline to a final concentration of 100 ~tg/h. After 3 h, the feedback somatostatin infusion was stopped whatever the blood glucose level in order to mimic the conditions of a pre-programmed infusion system. On day SOM, somatostatin was infused as on day sore but the somatostatin primed artificial pancreas was left in the closed-loop mode for the whole 8-h period.
Analytical Methods
Blood was taken from the ante-cubital vein of the non-infused arm. Heparinized blood was drawn continuously (1.3 ml/h) for continuous blood glucose determination using a Technicon autoanalyzer incorporated into our artificial pancreas [7] . In addition, 10ml blood were taken hourly and immediately centrifuged. Urine was collected every 4 h. D-Xylose was measured in plasma and urine by a colorimetric method [9] . Absence of interference with glucose was first verified. Immunoreactive plasma glucagon was measured using the Unger antibody 30 K [10] . Plasma growth hormone was measured by a double antibody technique [11] .
Statistical Methods
The results were expressed as mean • SEM. Differences between the mean results of the three periods were analyzed for statistical significance by Student's paired t test. 
Results Discussion
Insulin and Somatostatin Doses (Table 2) The mean basal insulin infusion rate was 1.0 + 0.1 U/h. An additional 18 +_ 3 U were infused postprandially on day INS by the artificial pancreas. Hence a total of 26 U was infused on day INS compared with 8 U on days som or SOM. The doses of somatostatin infused on days som and SOM were 550 + 89 and 1140 + 282 ~tg respectively at a rate of 357 + 37 and 287 + 44 ~tg/h. (Fig. 1) Post-prandial glycaemic excursions were similar with the three methods. Maximum blood glucose values were 7.7 + 0.6 mmol/1 at 69 + 7 min on day INS, 7.3 + 0.3 mmol/1 at 58 + 14 min on day som and 7.7 + 0.6 mmol/1 at 84 +_ 6 rain on day SOM. Blood glucose returned rapidly to the initial values on day INS but exhibited a large rebound on day som beginning immediately after the cessation of somatostatin infusion. Values on day SOM were intermediate, showing no rebound but a slower return to initial values which were not reached before 6 h.
Blood Glucose Control
Xylose
Plasma xylose results are shown on the lower part of The areas under the plasma xylose and total xylosurias curves were similar on days INS and som, but 25% lower on day SOM (p < 0.01) ( Table 3 ).
This study shows that in the presence of a basal infusion of insulin, the post-prandial rise in blood glucose seen in insulin-dependent diabetics may be as effectively controlled by a timed infusion of somatostatin as by insulin. Somatostatin infused at 300 ~tg/h was equivalent to an insulin dose of 18 units. Thus, a bi-hormonal system where mealtime infusions of somatostatin are superimposed on a continuous basal insulin infusion may reduce the hyperinsulinism which invariably occurs when doses of insulin are given prandially [2] , and consequently decrease the potential risks of high insulin levels [12] . On the other hand, the absence of any post-prandial increase of insulin values may result in abnormalities of amino-acid and lipid metabolism. In our experimental model, the antidiabetic effect of somatostatin seems to result from a decrease in carbohydrate absorption [13] [14] [15] , rather than a direct hormonal effect on blood glucose. The paradoxical findings of an unchanged growth hormone and glucagon [16] [17] may simply be due to their prior normalisation by the overnight insulin infusion [18] [19] [20] although transitory hormonal change cannot be excluded between the samples.
Christensen et al., studying patients in the fasting state, found similar glycaemic rebound to ourselves on stopping somatostatin infusion but also noted a parallel rebound of growth hormone and glucagon [17] . This apparently conflicting result may have been due to the lower infusion of insulin.
In conclusion therefore somatostatin could serve to replace post-prandial doses of insulin in an insulin dependent blood glucose regulating system and thus reduce the quantities of insulin infused. Somatostatin acts primarily by reducing or delaying carbohydrate absorption. Whilst this is less than the reduction seen in states of malabsorption, the potential long term consequences will require consideration and could limit the potential use of somatostatin.
